RCUS — Arcus Biosciences, Inc.

Is RCUS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Arcus Biosciences, Inc. (RCUS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $16.86. The rating moved from Neutral to Oversold on November 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Arcus Biosciences is a clinical‑stage oncology company with asymmetric upside tied to successful trial readouts or strategic partnerships, but the stock is exposed to high binary clinical and financing risk. Near-term performance will be sensitive to macro risk sentiment and any upcoming data or corporate news; stronger sector M&A interest provides a constructive backdrop, while cash‑runway and competitive pressures remain primary constraints.

Key factors

  • Pipeline-stage oncology focus with potentially high-value clinical catalysts that could re-rate the stock on positive readouts or partnership interest
  • Biotech sector-wide M&A and large-cap pharma appetite for specialty oncology assets, which increases upside from potential licensing or acquisition
  • Current market risk-off tone and defensive flows into staples/utilities, which can compress small-cap biotech performance near-term
  • Balance sheet and cash runway dynamics (typical for clinical-stage biotechs) drive dilution risk and near-term financing needs
  • Regulatory environment and payer scrutiny trends that affect commercialization prospects and long-term pricing/reimbursement

Risks

  • Clinical trial failures, disappointing interim or pivotal data, or safety signals that could cause steep share-price declines
  • High cash burn and need to raise capital, leading to dilution for current shareholders
  • Intense competition from well‑capitalized large‑cap pharma and other oncology developers targeting similar mechanisms
  • Regulatory or reimbursement headwinds (including increased Medicare/insurer scrutiny) that could reduce commercial economics
  • Broader market risk-off conditions and sector rotation away from small-cap biotech, amplifying volatility independent of fundamentals

See today's live rating, score and targets

Members see the live hourly rating for RCUS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.